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Significance 
Malignant pleural mesothelioma (MPM) is a devastating malignancy with a prognosis of less 
than 12 months. Even with bans on the use of asbestos in most Western countries, the 
incidence is still increasing due to the long latency periods between exposure and 
development of the disease. Diagnosis is often delayed due to invasive biopsies and lack of 
distinguishable markers. Patients frequently present with pleural effusions months to years 
before a radiologically detectable mass appears. This study aimed to investigate the 
proteome of pleural effusions taken from patients with MPM, adenocarcinoma and benign 
conditions in an attempt to identify a biomarker for early diagnosis. We identified several 
proteins that may be possible targets and warrant further investigation. Due to the 
predominance of up regulated proteins involved in VEGF signalling in MPM, we analysed 
VEGFA levels in effusions and found a strong correlation between VEGFA levels and 
survival in MPM. 
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Introduction:  
Malignant mesothelioma is a highly aggressive tumour of the mesothelial cells located on 
serosal membranes of the thoracic cavity, abdominal cavity and testis. Mesothelioma 
development is intimately linked with asbestos exposure [1, 2], however, whilst occupational 
exposure is still the most common source of contact, there are cases of non-occupational 
environmental exposure, such as individuals developing mesothelioma from living in close 
proximity to factories and previous mining sites such as Libby, Montana [3]. Despite bans on 
asbestos in most developed countries the incidence of mesothelioma is still increasing 
worldwide. This is attributable to the latency period, around 10 - 40 years, between exposure 
to asbestos and the development of the disease [4]. Asbestos is still present in the built 
environment, and further research is essential because exposures continues [5, 6].  
 
When asbestos fibres are inhaled a proportion is deposited in the lung tissue, and some 
translocate to the pleura. The fibres, especially amphiboles,  are characterised by 
biopersistence in the tissues, with a rate of clearance of only about 10-15% per year[7, 8] . It 
is now generally acknowledged that highly reactive free radicals such as reactive oxygen 
species (ROS) generated from the surface of asbestos fibres or from their interaction with 
macrophages have the capacity to damage DNA and induce gene mutations that contribute 
to mesothelioma development [9]. This is also supported by an animal model study 
conducted by Kodavanti et al. which demonstrated that asbestos inhalation causes systemic 
inflammation and a predisposition to malignancy [10]. 
 
Malignant pleural mesothelioma (MPM) comprises the majority of mesothelioma cases, 
approximately 90%, with an estimated 9% of tumours located in the peritoneal cavity and 
less than 1% located in the pericardium and tunica vaginalis testis [11, 12]. There are three 
main histological subtypes of mesothelioma which have implications for diagnosis and 
prognosis. The epithelioid subtype accounts for 60%, the sarcomatoid subtype between 10-
20%, and biphasic (mixed epithelioid and sarcomatoid) accounts for 30% [13, 14]. Kadota et 
al. reported the median survival length of epithelioid, biphasic and sarcomatoid subtypes are 
16.2, 7.0 and 3.8 months respectively [15]. Overall, the reported median survival time after 
diagnosis is about 12 months or less [16]. Treatment options are limited and patients with 
mesothelioma present with non-specific symptoms such as dyspnoea and chest wall pain. 
The lack of specific symptoms often contributes to a delay in diagnosis [17]. Mesothelioma 
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patients commonly present with pleural effusions months to years before a radiologically 
detectable mass develops. Effusions are drained for comfort and diagnosis, but cytology-
only diagnosis is rarely possible, and usually requires an invasive biopsy for confirmation 
[18]. If mesothelioma in situ could be identified at an early stage, targeted therapy may be 
possible and outcomes for patients might be improved. Whilst survival time at diagnosis is 
short, the long latency period also offers an opportunity to prevent the progression of the 
disease from initial exposure highlighting the need for improvements in diagnostic testing 
methods.  
 
Current mesothelioma biomarkers, such as BAP1, only have consistent utility for diagnosing  
MPM with an epithelioid component from pleural effusions in isolation, since cells are 
needed for diagnosis, and sarocmatoid mesotheliomas commonly do not shed cells [18]. 
Commonly proposed soluble biomarkers include soluble mesothelin-related protein (SMRP) 
[19-22], osteopontin (OPN) [22-24], CA125 [25], megakaryocyte potentiating factor [22, 26], 
hyaluronan [27], galectin-1  [28] and fibulin [29]. Many of these biomarkers have reasonable 
specificity and can help to differentiate mesothelioma from other pleural diseases. However, 
these proteins currently lack the sensitivity and specificity to be diagnostic alone [18] and 
negative results for these markers cannot exclude the possibility of mesothelioma. One 
study by Rai et al. using an ELISA assay analysed serum samples from MPM patients, 
healthy individuals and patients with other malignancies found consistently elevated 
concentrations of SMRP and OPN in mesothelioma, and the concentration of SMRP 
returned to normal following tumour resection [24].  
 
As pleural effusions are routinely taken from patients, we aimed to investigate the use of 
quantitative mass spectrometry as a tool to identify novel protein biomarkers in pleural 
effusion fluid associated with mesothelioma which could ultimately permit accurate and early 
diagnosis. Here we aim to use a new highly sensitive label free quantitative mass 
spectrometry (MS) technique called ‘sequential windowed acquisition of all theoretical 
fragment ion mass spectra (SWATH MS/MS) to compare pleural effusions from patients with 
benign reactive (BR) conditions, lung adenocarcinoma (AC) and MPM. We hope to validate 
this technology by identifying previous diagnostic and prognostic markers for mesothelioma 
and to identify potentially new diagnostic and treatment targets for MPM. To the best of our 
knowledge, there have only been 2 proteomic studies on the pleural effusions of 
mesothelioma patients [30, 31]. In the most recent study, Mundt et al. analysed pleural 
effusions from patients with mesothelioma (n=6), lung adenocarcinoma (n=6) and benign 
mesotheliosis (n=7). From the 1300 proteins identified, aldo-keto reductase 1B10, 
apolipoprotein C-I, galectin 1, myosin-VIIb, superoxide dismutase 2, tenascin C, and 
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thrombospondin 1 were found to be mesothelioma-specific markers and were validated 
using ELISA in a larger patient cohort  [31]. The other study Hegmans et al. examined 
pleural effusions from malignant mesothelioma (n=41) and compared them to effusions 
taken from patients with a range of conditions including other malignancies and non-infective 
inflammatory exudates (n=48). They identified SMRP as a reliable marker for mesothelioma 
and apolipoprotein CI as a potential discriminating marker using SELDI-TOF MS [30].  
 
Method: 
Pleural effusion samples 
Pleural effusions were collected from patients presenting at Flinders Medical Centre, South 
Australia. They were drained using thoracic thoracentesis and stored at -80°C until use. A 
total of 15 pleural effusion samples were selected from a series of 90 matched, clinically 
characterised effusion specimens based on shortest survival time. There were 5 MPM, 5 AC 
and 5 BR samples. All MPM samples were of the epithelioid subtype Patient demographics 
are presented in Table 1. This study was approved by the Southern Adelaide Health clinical 
human research Ethics Committee (Approval number 381/09) and the RAH Research Ethics 
Committee (Approval number 111215). 
 
Proteome purify removal of abundant proteins 
A summary of all experimental methods can be seen in Figure 1. In order to remove the top 
12 most abundant proteins which include albumin and immunoglobulins, 10 µL of sample 
were subject to sample clean up using a Protein PurifyTM depletion kit, (RnD systems, 
Minneapolis, USA). Briefly, this involved the addition of 1.0 mL immunodepletion resin to the 
sample, suspension using rotary shaker for 30 minutes and centrifuged for 2 min at 1000 x 
g. An EZQ protein assay (Life Technologies, California, USA) was carried out pre- and post-
depletion, according to the manufacturer’s recommendations. Each sample was analysed in 
triplicate, imaged using a Gel DocTM EZ gel documentation system (Biorad) and standard 
curves generation with the assistance of ImageLab (Biorad). 
 
Sample preparation for mass spectrometry 
In order to confirm equal loading of samples onto the mass spectrometer for quantitation, a 
secondary conformation of protein concentration was carried out. Ten μg of each sample 
was analysed on mini-PROTEIN® TGX Stain-freeTM precast gels (Biorad, California, USA). 
Following activation of the gel with UV light for 5 minutes, the fluorescent intensity of each 
lane was measured using a Gel DocTM EZ gel documentation system (Biorad, USA) coupled 
with Image Lab SoftwareTM to ensure equal concentration of proteins per sample. Following 
determination of protein concentration of the pleural effusion, 5µg of lysates were diluted in 
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100mM ammonium bicarbonate and reduced using 50µM dithiothreitol (DTT) for 30 minutes 
at 65°C and alkylated using 100µM iodoacetamide (IAA) in the dark for 60 minutes. MS 
grade Trypsin Gold was added a ratio of 1:25 and digested overnight at 37°C.   
SWATH MS/MS analysis of samples   
Samples were analysed in two phases, a data-dependent acquisition (DDA) followed by SWATH 
acquisition (data-independent analysis) on the same sample using the same gradient conditions. All 
samples were analysed using a Triple TOF 5600+ mass spectrometry (AB SCIEX, MA, USA) fitted with 
a nano-LC source. For the DDA run, peptides were separated using a Polar 3 µm precoloumn (0.3 X 
10 mm, SGE Analytical Science) and eluted onto a 5 µm C18column (75 mm x 150 mm with a bead 
pore size of 100 Å, NikkyoTechnos), using an Ekisgent Ekspert 416 nanoLC. The reverse phase LC 
solvents include solvent A (99.9% water + 0.1% formic acid) and solvent B (99.9% acetonitrile + 0.1% 
formic acid). A 140 minute gradient was used at a flow rate of 0.3µL/minute with the following 
elution conditions: 0-85 min, 97% A; 85-92 min, 75% A; 92-97 min, 5% A; 107-110, 5% B; 110-140, 
95% B. Between runs, the column was equilibrated by running 97% of solvent for 20 minutes before 
the next run.  
 
Peptides were injected into the MS using PicoTip™ SilicaTip™ electrospray emitte rs. For DDA 
acquisition, experiments were set to obtain a high-resolution TOF-MS scan over a mass range of 350 
– 1250 m/z, followed by 100 to 1250 m/z for MS/MS scans operating in high sensitivity mode. The 
selection criteria for the parent ions included the intensity of the ions had to be >200 cps, with a 
charge state of between 2 and 5. The dynamic exclusion was set for 30s after 2 occurrences. A 
50mDa mass tolerance was set and 100 maximum candidate ions were monitored per cycle. The ion 
accumulation time was set to 0.057s (MS) and 0.05s (MS/MS).  
 
Using the same conditions as described above, a SWATH acquisition was carried out using data-
independent analysis (DIA). Using a 140 minute gradient as detailed above and a cycle time of 5.861 
seconds, a variable isolation width including a 1Da overlap, a set of 60 windows were constructed, 
which covered a precursor mass range from 350 to 1250 Da. The high resolution mode was used to 
allow accurate extraction of the fragment ion masses. The total running time for each DDA and DIA 
injection was 120 minutes.  
 
Spectral library generation 
Data generated in the DDA run was searched against the Swiss-Prot protein database released on 
April 2017 using ProteinPilot (version 4.5 beta, AB SCIEX, USA) with the paragon algorithm and the 
following parameters: sample type – identification, alkylation - Iodoacetic acid, digestion -  
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trypsin, Instrument – TripleTOF5600, Special factors – nil, species – homo sapiens, ID focus 
with biological modifications, results quality of 0.05% confidence and false discovery rate 
analysis. The resulting Protein Pilot group file was used as the ion library file for all SWATH 
analysis and quantification.  
 
A table of precursor masses and fragment ions was created, this was used as a reference spe ctral 
library for targeted extraction to generate ion chromatograms (XIC) of fragment ions of targeted 
proteins and peptides in the SWATH processing microapp contained within the PeakView® software 
program (AbSciex, USA). Each peptide was manually examined and peak areas were integrated from 
the SWATH data files. The following search parameters were used: ion library mass tolerance –
50ppm; number of peptides –4; number of transitions –6; peptide confidence –95% and shared 
peptides were excluded. False discovery rates were performed. The output of this search (.group 
file) was used as the reference spectral library containing the following information: protein name 
and UniProt accession, peptide sequences, Q1 and Q3 ion detection, retention time, relative 
intensity, precursor charge, fragment type, score, confidence and decoy result.  
 
Swath acquisition, processing and targeted data extraction 
A 5µg aliquot of the peptides were used for each injection. Three samples were selected at random 
and technical replicates performed (Supplementary Figure 1). Targeted data extraction and spectral 
alignment of the SWATH samples (DIA run) was carried out using PeakView (AB SCIEX, USA) using  
the spectral library generated above.  All SWATH files were loaded and exported in .txt format using 
the following parameters: extraction window of 20 minutes, 4 peptides per protein, 6 transitions per 
peptide, XIC extraction window of 10 minutes and a width of 75ppm. 
 
Data export and analysis in OneOmics and BaseSpace 
In order to perform relative quantitation, the SWATH files were processed in PeakView and the 
output uploaded to BaseSpace (Illumina, California, USA) through the CloudConnect MicroApp in 
PeakView®. A three step process was carried out using the OneOmics microapps hosted in 
Basespace. 1) Samples were first processed using the Protein Expression Extractor Application (AB 
SCIEX, USA) and the following process parameters: 4 peptides per protein,  6 transitions per peptide, 
XIC extraction window of 10 minutes and a width of 75ppm. During this process, each .wiff file was 
extracted and interrogated using the uploaded spectral library. The metadata is defined in this 
application. 2) Protein Expression Assembler (AB SCIEX, USA) was used to select files and assign 
sample grouping. The data was normalized using the most likely ratio (MLR) by creating a ratio for 
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pairs of biological replicate within an experimental group. Using the MLR, the software makes  a ratio 
histogram between each single experimental group. The sample ratio histogram with the centroid 
closest to zero is used to align the other histograms for each of the samples within that experimental 
group (see supplementary data 1). This is used to create a normalized peak for each of the sample, 
from which a MLR weight is computed for each sample (measurement of reproducibility). The 
normalisation protocol was then repeated between allof the experimental groups. 3) In the final 
step, the Protein Expression Workflow Application (AB SCIEX, USA) was used to calculate fold 
changes, analyse sample clustering (PCA plots), FDR and protein ontology functions and processes. 
Proteins were considered as ‘significant changes’ if they fulfilled the predefined cr iteria of 
differential expression which was set at p value <0.05 (Benjamini -Hochberg corection) and a fold 
change of greater than >1.5 in ≥2 biological replicates. All fold changes are reported as log2-fold 
change. For a detailed description of the statistics carried out within OneOmics see Lambert 
et al, 2013 [32].  
 
Pathway analysis 
Pathway analysis was carried out using Enrichr (http://amp.pharm.mssm.edu/Enrichr/enrich). 
Differentially expressed proteins were used as input data and three different pathway 
databases were interrogated, KEGG 2016, Reactome 2016 and HumanCyc 2016. Data was 
exported as a table, and only pathways where 2 or more target proteins had been identified, 
and pathways with p values <0.05 were examined further.  
 
VEGF marker quantification using ELISA 
A larger cohort of patients was examined to investigate VEGF expression in MPM compared 
to AC and BR (Table 2). The pleural effusion samples were centrifuged at 500 x g for 5 
minutes at 25°C. The supernatant was then stored at -80°C until further use. The VEGFA 
ELISA was performed on pleural effusion supernatants using a human VEGFA DuoSet 
ELISA Development Kit (R&D Systems, Minneapolis, MN) according to manufacturer’s 
instructions. The plate was read at 450nm on the Versamax ELISA Microplate Reader 
(Molecular Devices, CA, US). Sample concentrations were calculated by comparison to the 
standard curve that was generated. A Kruskal-Wallis statistical analysis was used to 
determine whether any significant difference existed amongst the groups, followed by post-
hoc Mann-Whitney-U analysis. Significance was defined as p<0.05.  
 
Results and Discussion  
Pleural effusions, similar to the serum and plasma have a wide dynamic range of protein 
concentrations over at least 10 orders of magnitude. This makes the identification of low 
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abundance proteins, such as those as the pg/mL level difficult to detect using proteomic 
approaches. Depletion of high abundant proteins such as albumin, transferrin, haptoglobin 
and immunoglobulins is an essential step to improve the resolution of less abundant 
proteins. Our effusion spectral library clearly shows a predominance of proteins involved in 
the immune response, such as immunoglobulins, suggesting that depletion was not highly 
effective which may also be reflected by the low number of proteins identified in the pleural 
effusions, which totalled 284. To date, no other spectral libraries have been published on 
pleural effusions making comparison of our library with other studies impossible. Our library 
did include well known proteins present in malignant effusions including OPN and 
mesothelin. In order to increase the depth of the spectral library, we combined it with other 
libraries generated within the laboratory which were collected from patients with 
haematological malignancies. This brought the total number of proteins in the spectral library 
to 1425 (full library details in Supplementary Table 1). 
 
All samples were further acquired using a SWATH (DIA) approach. The first step was data 
inter- and intragroup normalization of all samples (Supplementary Figure 1A). One sample 
showed low overall counts and was subsequently reanalysed. The overall SWATH data 
quality including retention time, percentage of the coefficient of variation (CV) of transitions, 
peptides, and proteins across all biological and technical groups that matched the ion library 
were compared. The global expression profiles among the three groups were similar in 
terms of average signal intensity, which spanned more than four orders of magnitude in all 
three proteomes (Supplementary Figure 1B). This information indicated that a high quality 
data set suitable for SWATH quantification has been obtained. We performed technical 
replicates on three randomly selected samples from each group and the resulting PCA plot 
showed that the variation between technical replicates was low (Supplementary Figure 1C).   
 
A PCA plot of the individual samples were plotted and showed that the samples clustered 
into their respective groups. The benign group showed more of a spread, which is expected 
because the patients had different underlying causes of their effusions and therefore the 
protein expression between patients in this group is likely to be more variable (Figure 2A). 
Protein changes were also plotted as a volcano plot (Figure 2B) showing the spread of up- 
and down-regulated proteins at different confidence levels. In order to identify differentially 
expressed proteins, two stringency filters can be set based on either confidence values or 
corrected P-values. The heat map (Figure 2C) shows the key differentially expressed 
proteins between each group, these proteins met the highest filter stringency of >65% 
confidence, reproducibility of >0.1 and proteins must have had >2 peptides identified. We 
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identified a large number of immunoglobulin and complement related proteins, which have 
previously been reported to be found at high concentrations in malignant effusions [33, 34]. 
 
When we relaxed the confidence settings, but analysed the data based on Benjamini-
Hochberg corrected p-value we identified more differentially expressed proteins between the 
groups. We first analysed the protein differences between MPM and AC and identified 87 
differentially expressed proteins (p<0.05, Benjamini-Hochberg correction applied). 
Comparatively, we analysed the differences between MPM and BR effusions, where we 
identified 62 differentially expressed proteins. A full list of all proteins can be found in 
Supplementary Table 2 and the key protein differences for each can be seen in Tables 3 and 
4.  
 
Table 3 shows selected upregulated and downregulated proteins for MPM samples relative 
to lung AC samples respectively. Protein S100 was elevated 2.5 fold in MPM samples 
relative to AC samples. Similarly Table 4 showed Protein S100 was 2.1 fold greater in MPM 
relative to BR effusions. Protein S100 is normally present in cells derived from the neural 
crest and fat and performs a range of regulatory functions including phosphorylation, 
regulation of transcription factors, calcium homeostasis, cytoskeleton changes, enzyme 
activities, cell growth and differentiation and inflammation. The protein S100 family has been 
associated with a broad range of malignancies and there is evidence to suggest it has a role 
in tumorigenesis and metastasis [35].  Previous studies have not indicated protein S100 has 
a role in malignant mesothelioma: 2012 Guidelines for MPM diagnosis using 52 lung AC and 
51 MPM histological samples found S100 staining was positive in 19% of AC but completely 
absent in MPM samples [36]. Therefore, further research is required to assess the potential 
value of novel markers such as S100. 
 
Tables 3 and 4 showed cytokeratin 5 and 6 were significantly elevated in MPM relative to AC 
and cytokeratin 6 to BR samples. Both of these proteins have a key role in the diagnosis of 
MPM [18]. Cytokeratins 5/6 have been well established as a means of differentiating 
between MPM and lung AC [36, 37]. A review by Husain et al. states that they are expressed 
in 75% to 100% of mesotheliomas, compared to 2% to 20% of lung adenocarcinomas as 
determined by immunohistochemical staining. The use of cytokeratin 5/6 for distinguishing 
MPM from lung AC is supported by Chu and Weiss 2002.[37] However, it should be noted 
that work by Chu and Weiss demonstrated that other malignancies including transitional cell 
carcinoma, endometrial adenocarcinoma and breast adenocarcinoma have high rates of 
positive staining and can present challenges for diagnosis when metastatic disease is 
present in the pleura.  
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Fibronectin was elevated 2.2 fold in MPM relative to lung AC. This protein has a broad range 
of functions including cell adhesion, growth, migration and differentiation. Previous work by 
Klominek et al. indicates that fibronectin is locally synthesised by malignant mesothelial cells 
[38], indicating this molecule could be potential marker. At 2.1 and 2.4 fold respectively MPM 
effusions showed elevated 14-3-3 protein epsilon and 14-3-3 protein theta compared to AC 
effusions. 14-3-3 protein epsilon was also found elevated compared to BR effusions at 3.0 
fold. This family of proteins is ubiquitous in all eukaryotic organisms and is known to be 
involved in regulation of signalling pathways and 14-3-3 sigma has been strongly implicated 
in malignancies including breast, invasive ductal carcinoma, hepatocellular carcinoma and 
basal-cell carcinoma [39]. Typically the 14-3-3 proteins have an inhibitory role in the cell 
cycle  [40]. Although the epsilon subtype has not been implicated in mesothelioma, 14-3-3 
protein theta was found upregulated in malignant mesothelial lines in vitro relative to non-
malignant lines suggesting a link in tumorigenesis [41].  
 
Serum amyloid A-1 protein and serum amyloid A-2 protein were significantly upregulated in 
MPM compared to BR samples at 3.3 and 2.5 fold respectively. Serum amyloid proteins are 
a family of apolipoproteins associated with high density lipoproteins. They can be triggered 
by interleukin-6 which is known to be elevated with malignant mesothelioma, suggesting a 
link [42, 43]. The association between MPM-related inflammatory molecules and serum 
amyloid A-2 suggests this may have a role in prognosis. This result was partially consistent 
with MPM relative to AC where serum amyloid A-2 protein was significantly elevated in MPM 
(3.9 fold) but serum amyloid A-1 protein was higher in AC samples (1.8 fold). Galectins are 
well documented to play a role in MPM, with several studies identifying the importance of 
galectin-1 in MPM [31, 44] and the role of galectin-3 [45, 46]. Our results showed that 
galectin-3-binding protein was lower in MPM compared to BR. Galectin-3-binding protein is 
an endogenous β-galactoside-binding protein and has a role in cell growth, differentiation 
and malignant transformation. Studies have demonstrated a link between raised levels and 
MPM [47]. However, galectin-3-binding protein was elevated in MPM samples at 1.7 fold 
relative to AC samples. 
 
Figure 3A shows protein pathway differences between MPM and AC samples. Interestingly, 
signalling pathways predominate the analysis, including EGF receptor, FGF signalling, G-
protein signalling and VEGF signalling. Vascular endothelial growth factor (VEGF) promotes 
angiogenesis and has a well-established role in promoting MPM [48-51]. VEGF staining 
corelates with short survival (p = 0.0002), tumour stage (p = 0.046) and prognosis (p = 
0.001) in MPM [51]. Another study by Hirayama et al. found pleural effusion VEGF levels 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
were greater in patients with MPM compared to lung cancer and inflammatory conditions 
[52]. The study also found VEGF concentrations correlated with the stage of MPM. Due to 
the importance of VEGF signalling in MPM, we further characterised the role of this protein 
in our cohort (see below).  
 
We also noted a difference in several glycolysis proteins, like glyceraldehyde-3-phosphate 
dehydrogenase which catalyses the conversion of glyceraldehyde-3-phosphate to D-
glycerate-1,3-bisphosphate. This enzyme has a well-established role in tumorigenesis as it 
protects telomeres and increases metabolic rate. Additionally, this protein has found to be 
elevated in MPM exosomes [53]. Another enzyme involved in glycolysis, fructose-
bisphosphate aldolase was similarly found to be elevated in MPM samples relative AC 
samples: this is inconsistent with previous literature as this protein has been found to be 
moderately reduced in MPM relative to AC [54].  
 
Figure 3B shows the bioinformatic analysis of MPM compared to BR. The predominant 
pathways in this analysis were integrin cell surface interactions, ephrin B reverse signalling, 
urokinase-type plasminogen activation (uPA) and uPAR mediated signalling. Integrins are a 
family of adhesion molecules and play fundamental roles in cell growth, migration, survival 
and differentiation and modulate signalling events initiated by growth factors [55]. Integrins 
are expressed in MM cell lines [56] and they mediate migration towards ECM proteins like 
collagen and fibronectin. The ephrin B2 receptor is overexpressed in MPM but not in benign 
mesothelial cells and has been suggested as a potential therapeutic target in MPM [57]. 
uPAR (CD87) signalling plays an important role in numerous malignancies, including solid 
and haematological malignancies (16, 17). uPAR is increased in asbestos-induced rat MPM 
models and was associated with a significantly shorter survival [58].   
 
VEGF expression 
We identified VEGFA at elevated levels in MPM compared BR effusions (p < 0.001) (Figure 5A) but 
did not identify any statistically significant difference between the MPM and AC groups (p = 0.789). 
This is somewhat contradictory to our proteomic results. Whilst we did not identify VEGFA in our 
proteomic analysis, we did identify several proteins involved in VEGF signalling (e.g. PRKCB and 
PRKCD) but these were only differentially expressed in AC vs MPM. VEGFA was also significantly 
elevated in AC compared to the BR control group (p = 0.001), suggesting VEGFA and angiogenesis 
may have a role in lung cancers [52]. VEGF is an endothelial cell specific mitogen and has a well -
documented role in MPM. Almost all MPM cases are known to stain positive for VEGF [59] and it 
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appears to be a useful  prognostic serum based marker for screening individuals with known 
asbestos-exposure [60].  
 
MPM Survival and VEGFA levels 
Using the median level of VEGFA in MPM samples as a cut-off (1482 pg/ml), a statistically 
significant difference between the survival of low and high groups was found (p = 0.003). 
However, Hirayama et al. determined 2000 pg/ml as the optimal cut-off value between low 
and high VEGFA level in MPM pleural effusion samples [52]. This value also detected a 
significant difference in survival between low and high VEGFA in MPM pleural effusion 
samples (p = 0.02). In both cases high VEGFA was associated with a markedly reduced life 
expectancy, confirming VEGFA as a marker for poor MPM prognosis. Figure 5B shows a 
Kaplan-Meier curve for low and high VEGFA MPM groups using 2000 pg/ml as the cut-off 
value. The median survival length for the low VEGFA group was 12 months (CI 3.93-20.07, 
n = 15) whereas the median survival length for high VEGFA group was significantly reduced 
at 4 months (CI 1.65-6.35, n = 15). High VEGFA levels were significantly associated with 
poorer survival times (p = 0.002).  
 
Comparison to previous studies 
Whilst SWATH MS is a powerful label-free quantitation approach, combining the advantages 
of high-throughput shotgun proteomics seen in traditional data-dependent acquisition (DDA) 
approaches with the reproducibility of selected reaction monitoring (SRM). Its data 
independent acquisition (DIA) approach provides a more reproducible coverage, for 
example, SWATH MS conferred a 15-20% increase in reproducible peptide identification and 
a 54% increase in the number of proteins identified in liver samples compared to traditional 
DDA approaches [61]. However, the method does come with limitations as retrospective 
interrogation of the samples is needed using spectral libraries, therefore, the identification of 
proteins is dependent on their initial identification in these libraries.  
 
To date, there have been two other proteomic studies of pleural effusions in MPM [30, 31]. 
Using SELDI-TOF, cytokeratin 19 fragment (CYAFR 21-1) and SMRP were found to be 
significantly higher in MPM samples compared to non-MPM effusions, whereas ApoC1 was 
found at lower levels [30] . They did not identify any difference in OPN levels between MPM 
and non-MPM samples. In our study, we failed to identify SMRP, but we did find several 
differences for the cytokeratin family and in most cases found higher levels of keratin in 
MPM compared to AC and benign effusions. We also identified several Apo protein family 
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members, although all failed to meet our high confidence criteria from the Protein Expression 
workflow.  
 
The most detailed study of pleural effusions in MPM was carried out by Mundt et al (2014), 
who used an iTRAQ based quantitation approach. They identified galectin-1 as an important 
diagnostic marker to distinguish between AC and MPM, with lower levels identified in MPM. 
They also found high levels of aldo-keto reductase and lower levels of APOC-1 confer a 
shorter survival. Whilst several galectin 1 peptides were identified in our initial spectral 
library, galectin-1 failed to be detected in the quantitation runs. This is an interesting, but not 
surprising observation. Jylha et al (2018)[62] found there was only a 60% overlap in proteins 
identified from the same samples that had been analysed using both iTRAQ and SWATH, 
which may explain the discrepancy noted between our study and that of Mundt et al [62]. 
However, we did note a higher level of aldo-keto reductase in AC vs MPM (+2.6 fold).  
 
Conclusion: 
In the era of liquid biopsies and personalised medicine approaches it is becoming clear that 
the ability to diagnose and monitor disease is fundamental to the success of treatments. In 
MPM, this is further reiterated by complexities in current diagnostic methods leading to 
delays in essential treatment. The identification of a predictive biomarker could be useful to 
monitor individuals who have had prior asbestos exposure in their profession or 
environmental exposure, such as Libby, Montana (USA). This study did not identify some of 
the previously proposed diagnostic or biomarkers, such as calretinin and hyaluronic acid in 
MPM samples. However, cytokeratin 5/6 was significantly elevated in MPM compared to AC 
and BR effusions. Serum amyloid protein-2 was found consistently elevated in MPM 
compared to both AC and BR indicating this peptide may have a role in prognosis and 
diagnosis. Additionally novel molecules protein S100, 14-3-3 epsilon, 14-3-3 theta and 
fibronectin were found elevated in MPM samples and are worthy of further exploration. 
Pathway analysis has shown there are differences in glycolysis and VEGF signalling 
between MPM and lung AC, and this is an important finding. The relevance of VEGF to 
tumour progression and ultimately prognosis in metastatic tumours is well established, 
including for this cohort of patients. However, clinical response to anti-VEGF therapies has 
been limited, and a deeper understanding of the processes involved may lead to improved 
therapy. However, it is important to acknowledge the limitations of this study as the small 
sample size could impact on the reliability and further work with more samples and high 
longevity patients is required. Furthermore, this study highlights that the depletion of 
dominant effusion proteins such as immunoglobulins and complement factors is essential to 
increase the sensitivity and identification of lower abundant protein species. 
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Supplementary Figure 1: a) The first step in the SWATH analysis is data normalization, 
which was carried out using the most likely ratio (MLR) within the Protein Extractor and 
Assembler applications using BaseSpace. The sample depicted in the pink line showed low 
counts and was re-acquired. b) The distribution of peptide signal intensities for MPM (blue 
line), AC (orange line) and reactive effusions (green line) plotted in a semi-logarithmic scale 
using OneOmics. The dynamic range plot shows the distribution of peptide intensities across 
the samples that have at least one confident detection (<1% FDR). c) 3 technical replicates 
of a randomly chosen sample from each experimental group were analysed. The tight 
clustering suggests that the acquisition of the replicates was reproducible. 
 
Supplementary Table 1: Spectral library. Complete list of proteins isolated from pleural 
effusions (listed on first tab) as well as libraries previously constructed in the lab from 
patients with haematological malignancies (tab 2 – other spectral library). There were 
identified using data dependent acquisition on the TripleTOF 5600+ (AbSciex) and searched 
using ProteinPilot with the Pargon algorithm (for further details see methods section). 
 
Supplementary Table 2: Full list of all differentially expressed proteins between MPM, AC 
and BR effusions including Uniprot Assession ID. Differential expression was measured as 
reported in the methods section and presented as signed fold change (sfc), log2 sign fold 
change, MLR ratios and P-values.  MLR ratios and P-values were determined by the Protein 
Expression Assembler application hosted on the BaseSpace cloud based analysis software 
(Illumina). Data is presented across three tabs for the various comparisons (AC vs MPM; BR 
vs MPM and BR vs AC). 
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Figure 1: Summary of the methods used in this study. Pleural effusions were drained by 
thoracentesis. Five samples were selected from each of the patient groups and abundant 
proteins were depleted from each effusion. Each of the individual samples was acquired 
using DDA methods and the results were analysed using ProteinPilot to generate a .group 
file containing the spectral library information. Further to this, an in-house generated spectral 
library was combined with the effusion library to increase the number of total proteins of the 
library to 1425 with 2203 peptides and 13,109 transitions. All 15 samples were also acquired 
using a DIA (SWATH). This generated 15 .wiff files containing all of the quantitative 
information. Using the CloudConnect uploader the .wiff files were loaded into BaseSpace 
(Illumina). Protein Extractor application was used to extract and integrate the peptide peaks 
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using the ion spectral library to generate .qresult file. Within Protein Extractor, the 
experimental metadata is defined, the data is normalized using the method described in 
Lambert et al, [32] and the protein fold changes are computed. This is further refined in 
Protein Assembler to generate an .fca file. The .fca file first undergoes analytics assessment 
to ensure the MS data is of a high quality (Supplementary Figure 1). The data is then 
analysed in the OneOmics Browser (Figure 2). OneOmics uses a more sophisticated 
method where fold changes and confidence values are computed for each protein across the 
groups, P-values are then corrected (Bejamini-Hochberg correction).  
 
Figure 2: OneOmics data analysis. (A) A PCA plot was carried out with each individual 
sample. This stastistical method compares the data across multiple samples and reveal 
groupings among the data sets, as shown in the score plot. The biological replicates show 
more variance, although the MPM and AC samples do cluster into different regions on the 
score plot. The reactive group is more variable, likely due to the different underlying 
diseases represented in this group. The settings used for the PCA plot are a Weighting of 
None and Pareto Scaling.  (B) A pseudo-volcano plot showing the degree of fold change 
(log2) and the confidence of the protein expressions. Each dot represents a pairwise 
comparison of the experimental group (AC and reactive) to the defined control group (MPM). 
(C) A heat map generated in OneOmics showing proteins that met the highest filter 
stringency of >65% confidence, reproducibility of >0.1 and proteins must have had >2 
peptides identified. Log2 fold change values are depicted.   
 
Figure 3: Pathway analysis of protein differences analysed using Enrichr. (A) Analysis 
of MPM vs AC effusions. SWATH analysis revealed 87 proteins as differentially expressed 
between MPM and AC effusions. Bioinformatic analysis using the Panther database shows 
that these proteins clustered predominately into signalling pathways, such as FGF, EGR and 
VEGF. (B) Pathway analysis of MPM vs BR effusions. SWATH analysis revealed 62 
differentially expressed proteins between MPM and BR effusions. Bioinformatic analysis was 
carried out using the Reactome database. The differentially expressed proteins clustered 
into integrin cell surface interactions, ephrin B signalling and urokinase-type plasminogen 
activator (uPAR) signalling.  
 
Figure 4: (A) Using an ELISA based approach, the levels of VEGFA were measured in 
pleural effusions isolated from BR (n = 30), MPM (n = 30) and AC (n = 30) patients. 
VEGFA was found at higher levels in patients with MPM and AC compared to those 
with BR effusions. ○ represent outliers (> 1.5x the interquartile range); ▲ represents 
extreme outlier (> 3x the interquartile range); * indicates p < 0.05. (B) Kaplan-Meier 
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survival curves for low and high VEGFA in MPM effusions. The median survival time for 
the low VEGFA group was 12 months (CI 3.93-20.07, n = 15), compared to 4 months for the 
high VEGFA group (CI 1.65-6.35, n = 15). This difference was found to be statistically 
significant (p = 0.002). 
 
 
 
 
 
 
 
Table 1: Demographics of patients used in this study 
Parameter Malignant Pleural 
Mesothelioma 
Lung 
Adenocarcinoma 
Benign Reactive 
Total number 
(genders) 
 5 (3M, 2F) N = 5 (3M, 2F) N = 5 (3M, 2F) 
Age (Range) in 
years  
76 (67-77) 74 (64-78) 70 (65-77) 
Mean Survival time 
(months) 
3.2 4.2 16.6 
 
 
 
Table 2: Patient demographics used for quantification of VEGF expression 
Group MM Adenocarcinoma Reactive 
Total number 
(Males) 
30 (26) 30 (25) 30 (26) 
Age (Range) in 
years 
75 (55-94) 75 (58-89) 74 (55-94) 
Subtype Epithelioid (27) 
Biphasic (2) 
Sarcomatoid 
(1) 
Lung (25) 
Breast (1) 
Endometrial 
(1) 
Colon (1) 
N/A 
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Table 3: Selected relative protein change for MPM and AC effusions. Benjamini-
Hochberg corrections were applied and only proteins that were significant are reported. 
 
Protein 
symbol 
Protein Name Gene Elevated Upregulated 
Fold  (log2) 
P 
value 
R4GN98 Protein S100 S100A6 MPM 2.5 5.40E-
05 
K2C6C Keratin, type II 
cytoskeletal 6C 
KRT6C MPM 3.9 0.0192 
SAA2 Serum amyloid A-2 
protein 
SAA2 MPM 3.9 0.0370 
V9HVZ4 Glyceraldehyde-3-
phosphate 
dehydrogenase 
GAPDH MPM 3.1 0.0350 
K2C5 Keratin, type II 
cytoskeletal 5 
KRT5 MPM 3.1 0.0157 
1433T 14-3-3 protein theta YWHAQ MPM 2.4 0.0286 
K2C6A Keratin, type II 
cytoskeletal 6A 
KRT6A MPM 2.3 0.0250 
FINC Fibronectin FN1 MPM 2.2 0.0479 
1433E 14-3-3 protein epsilon YWHAE MPM 2.1 0.0184 
V9HWN7 Fructose-bisphosphate 
aldolase 
ALDOA MPM 2.6 0.0131 
LG3BP Galectin-3-binding 
protein 
LGALS3BP MPM 1.7 0.0489 
SAA1 Serum amyloid A-1 
protein 
SAA1 AC 1.8 0.0281 
KPCB Protein kinase C beta 
type 
PRKCB AC 2.4 5.4E-
05 
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Table 4: Selected relative protein change for MPM and BR effusions. Benjamini-
Hochberg corrections were applied and only proteins that were significant are reported. 
Protein 
Symbol 
Protein Name Gene Elevated Upregulated 
Fold  (log2) 
P value 
K2C6C Keratin, type II 
cytoskeletal 6C 
KRT6C MPM 6.6 0.0167 
SAA1 Serum amyloid A-1 
protein 
SAA1 MPM 3.3 0.0326 
1433E 14-3-3 protein epsilon YWHAE MPM 3.0 0.00438 
PPIB Peptidyl-prolyl cis-
trans isomerase B 
PPIB MPM 2.7 0.0257 
SAA2 Serum amyloid A-2 
protein 
SAA2 MPM 2.5 0.0349 
R4GN98 Protein S100 S100A6 MPM 2.1 0.0350 
K2C6A Keratin, type II 
cytoskeletal 6A 
KRT6A MPM 1.9 0.0228 
LG3BP Galectin-3-binding 
protein 
LGALS3BP BR 3.3 0.0426 
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Highlights: 
 
 Key proteins upregulated in mesothelioma include S100 proteins and cytokeratin 5/6 
 Serum amyloid protein-2 may have a role in prognosis and diagnosis of 
mesothelioma 
 Proteins involved in VEGF signalling are increased in mesothelioma 
 VEGFA is a marker for poor prognosis in mesothelioma 
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